FROM SERUM DYSLIPIDEMIA TO MACROPHAGE LIPID REMODELING IN VISCERAL LEISHMANIASIS: CHOLESTEROL TRAFFICKING, IMMUNOMETABOLIC REPROGRAMMING, AND THERAPEUTIC OPPORTUNITIES

Authors

  • Rubens Barbosa Rezende Author

Keywords:

Visceral leishmaniasis; Lipid metabolism; Macrophages; Cholesterol; Immunometabolism.

Abstract

This structured narrative review examines the relationship between systemic dyslipidemia, macrophage lipid remodeling, and immunometabolism in visceral leishmaniasis (VL). Clinical and experimental evidence was gathered primarily from PubMed/MEDLINE, complemented by reference tracking and institutional sources, with the final literature update on 21 September 2026. The reviewed studies indicate that active VL is often characterized by lower total cholesterol, HDL, LDL, and apolipoprotein A-I, together with elevated triglycerides; recurrent episodes associated with HIV coinfection may instead show more generalized lipid depletion. In macrophages, infection modifies cholesterol-rich membrane domains, endolysosomal trafficking, and lipid-droplet accumulation, involving pathways such as SREBP, mTOR, PPARγ, LXR, ABCA1, and FABP4/CD36. These changes are associated with antigen presentation, reactive-species production, and the IL-10/IL-12 balance, potentially affecting parasite persistence and therapeutic responsiveness. Systemic and intracellular lipid alterations are therefore distinct but interconnected phenomena. Composite biomarkers and interventions targeting specific metabolic compartments are promising directions, although they require validation in longitudinal patient studies.

References

ADEME, M. et al. T-cell and soluble co-inhibitory receptor expression in patients with visceral leishmaniasis are markers of treatment response and clinical outcome. Open Forum Infect Dis, v. 11, n. 11, art. ofae649, 2024. DOI: 10.1093/ofid/ofae649.

ARAÚJO, M. et al. Intramacrophage lipid accumulation compromises T cell responses and is associated with impaired drug therapy against visceral leishmaniasis. Immunology, v. 170, n. 4, p. 510-526, 2023. DOI: 10.1111/imm.13686.

ARAÚJO-SANTOS, T. et al. Role of prostaglandin F2α production in lipid bodies from Leishmania infantum chagasi: insights on virulence. J Infect Dis, v. 210, n. 12, p. 1951-1961, 2014. DOI: 10.1093/infdis/jiu299.

BANERJEE, S. et al. Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infect Immun, v. 77, n. 6, p. 2330-2342, 2009. DOI: 10.1128/IAI.00057-09.

BRUHN, K. W. et al. LXR deficiency confers increased protection against visceral Leishmania infection in mice. PLoS Negl Trop Dis, v. 4, n. 11, art. e886, 2010. DOI: 10.1371/journal.pntd.0000886.

CARVALHO, M. D. T. et al. Lipoprotein lipase and PPAR alpha gene polymorphisms, increased very-low-density lipoprotein levels, and decreased high-density lipoprotein levels as risk markers for the development of visceral leishmaniasis by Leishmania infantum. Mediators Inflamm, v. 2014, art. 230129, 2014. DOI: 10.1155/2014/230129.

CHAKRABORTY, D.; BANERJEE, S.; SEN, A.; BANERJEE, K. K.; DAS, P.; ROY, S. Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J Immunol, v. 175, n. 5, p. 3214-3224, 2005. DOI: 10.4049/jimmunol.175.5.3214.

CHAN, M. M.; ADAPALA, N.; CHEN, C. Peroxisome proliferator-activated receptor-γ-mediated polarization of macrophages in Leishmania infection. PPAR Res, v. 2012, art. 796235, 2012. DOI: 10.1155/2012/796235.

CHAPARRO, V. et al. Translational profiling of macrophages infected with Leishmania donovani identifies mTOR- and eIF4A-sensitive immune-related transcripts. PLoS Pathog, v. 16, n. 6, art. e1008291, 2020. DOI: 10.1371/journal.ppat.1008291.

CHAWLA, A. et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell, v. 7, n. 1, p. 161-171, 2001. DOI: 10.1016/S1097-2765(01)00164-2.

FERNÁNDEZ-GARCÍA, M. et al. Leishmania donovani induces multiple dynamic responses in the metabolome associated with amastigote differentiation and maturation inside the human macrophage. J Proteome Res, v. 22, n. 7, p. 2256-2270, 2023. DOI: 10.1021/acs.jproteome.2c00845.

GATTO, M. et al. Biochemical and nutritional evaluation of patients with visceral leishmaniasis before and after treatment with leishmanicidal drugs. Rev Soc Bras Med Trop, v. 46, n. 6, p. 735-740, 2013. DOI: 10.1590/0037-8682-0198-2013.

GAUTAM, S. et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis, v. 204, n. 7, p. 1134-1137, 2011. DOI: 10.1093/infdis/jir461.

GAUTAM, S. et al. CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis, v. 209, n. 2, p. 290-299, 2014. DOI: 10.1093/infdis/jit401.

GHOSH, J.; GUHA, R.; DAS, S.; ROY, S. Liposomal cholesterol delivery activates the macrophage innate immune arm to facilitate intracellular Leishmania donovani killing. Infect Immun, v. 82, n. 2, p. 607-617, 2014. DOI: 10.1128/IAI.00583-13.

HABIB, S. et al. PDL-1 blockade prevents T cell exhaustion, inhibits autophagy, and promotes clearance of Leishmania donovani. Infect Immun, v. 86, n. 6, art. e00019-18, 2018. DOI: 10.1128/IAI.00019-18.

KAUSAR, G. et al. Apolipoprotein E is upregulated in blood and circulating monocytes of Indian patients with visceral leishmaniasis. Parasite Immunol, v. 46, n. 5, art. e13036, 2024. DOI: 10.1111/pim.13036.

KUMAR, G. A.; ROY, S.; JAFURULLA, M.; MANDAL, C.; CHATTOPADHYAY, A. Statin-induced chronic cholesterol depletion inhibits Leishmania donovani infection: relevance of optimum host membrane cholesterol. Biochim Biophys Acta Biomembr, v. 1858, n. 9, p. 2088-2096, 2016. DOI: 10.1016/j.bbamem.2016.06.010.

KUMAR, A. et al. Leishmania infection activates host mTOR for its survival by M2 macrophage polarization. Parasite Immunol, v. 40, n. 11, art. e12586, 2018. DOI: 10.1111/pim.12586.

KUMAR, V. et al. ApoA1-driven cholesterol efflux and macrophage polarization orchestrate T-cell differentiation towards controlling Leishmania donovani pathogenesis. Sci Rep, v. 16, art. 586, 2026. DOI: 10.1038/s41598-025-30130-1.

LI, F. R. et al. Single-cell transcriptomics reveals lipid metabolism reprogramming in macrophages in vitro during early stages of Leishmania donovani infection. Parasit Vectors, v. 19, art. 176, 2026. DOI: 10.1186/s13071-026-07361-w.

LIBEROPOULOS, E. N. et al. Visceral leishmaniasis is associated with marked changes in serum lipid profile. Eur J Clin Invest, v. 44, n. 8, p. 719-727, 2014. DOI: 10.1111/eci.12288.

LIMA, J. B. et al. Leishmania infantum lipophosphoglycan induced-prostaglandin E2 production in association with PPAR-γ expression via activation of Toll like receptors-1 and 2. Sci Rep, v. 7, art. 14321, 2017. DOI: 10.1038/s41598-017-14229-8.

MAJUMDER, S. et al. Leishmania-induced biphasic ceramide generation in macrophages is crucial for uptake and survival of the parasite. J Infect Dis, v. 205, n. 10, p. 1607-1616, 2012. DOI: 10.1093/infdis/jis229.

MESQUITA, I. et al. The absence of HIF-1α increases susceptibility to Leishmania donovani infection via activation of BNIP3/mTOR/SREBP-1c axis. Cell Rep, v. 30, n. 12, p. 4052-4064.e7, 2020. DOI: 10.1016/j.celrep.2020.02.098.

MUKHERJEE, M.; BASU BALL, W.; DAS, P. K. Leishmania donovani activates SREBP2 to modulate macrophage membrane cholesterol and mitochondrial oxidants for establishment of infection. Int J Biochem Cell Biol, v. 55, p. 196-208, 2014. DOI: 10.1016/j.biocel.2014.08.019.

NOGUEIRA, V. B. et al. Impaired signaling pathways on Berardinelli-Seip congenital lipodystrophy macrophages during Leishmania infantum infection. Sci Rep, v. 14, art. 11236, 2024. DOI: 10.1038/s41598-024-61663-6.

OTTONI, C. I.. A infecção por Leishmania infantum chagasi altera o metabolismo lipídico do hospedeiro. 2010. Dissertação – Universidade Federal do Rio Grande do Norte, Natal, 2010.

PRADHAN, S. et al. Scrutinized lipid utilization disrupts Amphotericin-B responsiveness in clinical isolates of Leishmania donovani. eLife, v. 14, art. RP102857, 2025. DOI: 10.7554/eLife.102857.

PRAKASH, S.; SAINI, S.; KUMARI, S.; SINGH, B.; KUREEL, A. K.; RAI, A. K. Retinoic acid restores the levels of cellular cholesterol in Leishmania donovani infected macrophages by increasing npc1 and npc2 expressions. Biochimie, v. 198, p. 23-32, 2022. DOI: 10.1016/j.biochi.2022.03.002.

PUCADYIL, T. J.; TEWARY, P.; MADHUBALA, R.; CHATTOPADHYAY, A. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol Biochem Parasitol, v. 133, n. 2, p. 145-152, 2004. DOI: 10.1016/j.molbiopara.2003.10.002.

RABHI, S. et al. Lipid droplet formation, their localization and dynamics during Leishmania major macrophage infection. PLoS One, v. 11, n. 2, art. e0148640, 2016. DOI: 10.1371/journal.pone.0148640.

RODRÍGUEZ, N. E.; GAUR, U.; WILSON, M. E. Role of caveolae in Leishmania chagasi phagocytosis and intracellular survival in macrophages. Cell Microbiol, v. 8, n. 7, p. 1106-1120, 2006. DOI: 10.1111/j.1462-5822.2006.00695.x.

RODRÍGUEZ, N. E.; GAUR DIXIT, U.; ALLEN, L. A. H.; WILSON, M. E. Stage-specific pathways of Leishmania infantum chagasi entry and phagosome maturation in macrophages. PLoS One, v. 6, n. 4, art. e19000, 2011. DOI: 10.1371/journal.pone.0019000.

SEMINI, G. et al. Changes to cholesterol trafficking in macrophages by Leishmania parasites infection. MicrobiologyOpen, v. 6, n. 4, art. e00469, 2017. DOI: 10.1002/mbo3.469.

SILVA, R. V. S. et al. Low plasma lipids are associated with relapsing and lethal visceral leishmaniasis in HIV-infected patients. Pathogens, v. 13, n. 6, art. 450, 2024. DOI: 10.3390/pathogens13060450.

SOARES, N. M. et al. Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages. Parasite Immunol, v. 32, n. 4, p. 259-266, 2010. DOI: 10.1111/j.1365-3024.2009.01187.x.

TABREZ, S. et al. Leishmania donovani modulates macrophage lipidome during infection. Parasite Immunol, v. 46, n. 8-9, art. e13066, 2024. DOI: 10.1111/pim.13066.

TSIMIHODIMOS, V.; KEI, A.; APOSTOLOU, F.; ELISAF, M. Diagnostic lipid changes in patients with visceral leishmaniasis. Hosp Pract (1995), v. 46, n. 4, p. 229-232, 2018. DOI: 10.1080/21548331.2018.1483171.

VARELA, M. G. et al. Association between hypertriglyceridemia and disease severity in visceral leishmaniasis. Am J Trop Med Hyg, v. 106, n. 2, p. 643-647, 2022. DOI: 10.4269/ajtmh.21-0260.

WORLD HEALTH ORGANIZATION. Leishmaniasis. Global Health Observatory and WHO fact sheet. Geneva: WHO, 2026. Accessed on: September 19, 2026.

Downloads

Published

2026-10-31

Issue

Section

Articles

How to Cite

FROM SERUM DYSLIPIDEMIA TO MACROPHAGE LIPID REMODELING IN VISCERAL LEISHMANIASIS: CHOLESTEROL TRAFFICKING, IMMUNOMETABOLIC REPROGRAMMING, AND THERAPEUTIC OPPORTUNITIES. (2026). ISIR Journal of Business and Management Studies (ISIRJBMS), 3(5), 45-55. https://isirpublisher.com/index.php/isirjbms/article/view/48

Most read articles by the same author(s)